Changes in vitamin D metabolism during natural and medical menopause.

Hartwell D, Riis BJ, Christiansen C

The Journal of clinical endocrinology and metabolism1 Jul 1990Cited by 23 (Europe PMC)

PMID2142491DOI10.1210/jcem-71-1-127PepBankPUB-02142491

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialMechanism
In premenopausal women with endometriosis, nafarelin alone at 200 micrograms significantly decreased the free index of 1,25-(OH)2D.
In plain wordsIn women with endometriosis, nafarelin alone at 200 micrograms reduced the free index of active vitamin D.
Peptide
Nafarelin
Outcome
DecreaseFree index of 1,25-(OH)2D during treatment
Study
n: not reported in source
Outcome group
Hormone levels · Endocrine and hormones
Studied dose
200 micrograms · 6 monthsAs given in this study (human).
Source sentences
Summary
All three nafarelin groups had a significantly decreased free index of 1,25-(OH)2D, which returned to the baseline value on withdrawal of the treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
The same variables were studied in 42 premenopausal women with endometriosis treated for 6 months with nafarelin acetate (a LHRH agonist) given alone in a dose of 200 or 400 micrograms or in a dose of 400 micrograms combined with 1.2 mg norethisterone (NET)/day and followed-up for a further 6 months.
Report a problemFND-0214249101
02HumanNon-randomized trialMechanism
In premenopausal women with endometriosis, nafarelin alone at 400 micrograms significantly decreased the free index of 1,25-(OH)2D.
In plain wordsIn women with endometriosis, nafarelin alone at 400 micrograms reduced the free index of active vitamin D.
Peptide
Nafarelin
Outcome
DecreaseFree index of 1,25-(OH)2D during treatment
Study
n: not reported in source
Outcome group
Hormone levels · Endocrine and hormones
Studied dose
400 micrograms · 6 monthsAs given in this study (human).
Source sentences
Summary
All three nafarelin groups had a significantly decreased free index of 1,25-(OH)2D, which returned to the baseline value on withdrawal of the treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
The same variables were studied in 42 premenopausal women with endometriosis treated for 6 months with nafarelin acetate (a LHRH agonist) given alone in a dose of 200 or 400 micrograms or in a dose of 400 micrograms combined with 1.2 mg norethisterone (NET)/day and followed-up for a further 6 months.
Report a problemFND-0214249102
03HumanNon-randomized trialMechanism
In women with endometriosis, the free index of 1,25-(OH)2D, which had decreased during nafarelin alone at 200 micrograms, returned to the baseline value on withdrawal.
In plain wordsIn women with endometriosis, the free index of active vitamin D went back to its starting value after low-dose nafarelin was stopped.
Peptide
Nafarelin
Outcome
IncreaseFree index of 1,25-(OH)2D after withdrawal
Study
n: not reported in source
Outcome group
Hormone levels · Endocrine and hormones
Studied dose
200 micrograms · 6 monthsAs given in this study (human).
Source sentences
Summary
All three nafarelin groups had a significantly decreased free index of 1,25-(OH)2D, which returned to the baseline value on withdrawal of the treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
The same variables were studied in 42 premenopausal women with endometriosis treated for 6 months with nafarelin acetate (a LHRH agonist) given alone in a dose of 200 or 400 micrograms or in a dose of 400 micrograms combined with 1.2 mg norethisterone (NET)/day and followed-up for a further 6 months.
Report a problemFND-0214249103
04HumanNon-randomized trialMechanism
In women with endometriosis, the free index of 1,25-(OH)2D, which had decreased during nafarelin alone at 400 micrograms, returned to the baseline value on withdrawal.
In plain wordsIn women with endometriosis, the free index of active vitamin D went back to its starting value after high-dose nafarelin was stopped.
Peptide
Nafarelin
Outcome
IncreaseFree index of 1,25-(OH)2D after withdrawal
Study
n: not reported in source
Outcome group
Hormone levels · Endocrine and hormones
Studied dose
400 micrograms · 6 monthsAs given in this study (human).
Source sentences
Summary
All three nafarelin groups had a significantly decreased free index of 1,25-(OH)2D, which returned to the baseline value on withdrawal of the treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
The same variables were studied in 42 premenopausal women with endometriosis treated for 6 months with nafarelin acetate (a LHRH agonist) given alone in a dose of 200 or 400 micrograms or in a dose of 400 micrograms combined with 1.2 mg norethisterone (NET)/day and followed-up for a further 6 months.
Report a problemFND-0214249104
05HumanNon-randomized trialMechanism
In women with endometriosis, vitamin D-binding protein remained unchanged with nafarelin alone at 200 micrograms.
In plain wordsIn women with endometriosis, vitamin D-binding protein stayed unchanged with low-dose nafarelin alone.
Peptide
Nafarelin
Outcome
No significant changeVitamin D-binding protein
Study
n: not reported in source
Outcome group
Hormone levels · Endocrine and hormones
Studied dose
200 micrograms · 6 monthsAs given in this study (human).
Source sentences
Summary
Vitamin D-binding protein showed a small transient increase in the nafarelin plus NET group, but was unchanged in the other two groups.
1 context sentence(design, population, supporting numbers)
Summary · context
The same variables were studied in 42 premenopausal women with endometriosis treated for 6 months with nafarelin acetate (a LHRH agonist) given alone in a dose of 200 or 400 micrograms or in a dose of 400 micrograms combined with 1.2 mg norethisterone (NET)/day and followed-up for a further 6 months.
Report a problemFND-0214249105
06HumanNon-randomized trialMechanism
In women with endometriosis, vitamin D-binding protein remained unchanged with nafarelin alone at 400 micrograms.
In plain wordsIn women with endometriosis, vitamin D-binding protein stayed unchanged with high-dose nafarelin alone.
Peptide
Nafarelin
Outcome
No significant changeVitamin D-binding protein
Study
n: not reported in source
Outcome group
Hormone levels · Endocrine and hormones
Studied dose
400 micrograms · 6 monthsAs given in this study (human).
Source sentences
Summary
Vitamin D-binding protein showed a small transient increase in the nafarelin plus NET group, but was unchanged in the other two groups.
1 context sentence(design, population, supporting numbers)
Summary · context
The same variables were studied in 42 premenopausal women with endometriosis treated for 6 months with nafarelin acetate (a LHRH agonist) given alone in a dose of 200 or 400 micrograms or in a dose of 400 micrograms combined with 1.2 mg norethisterone (NET)/day and followed-up for a further 6 months.
Report a problemFND-0214249106
07HumanNon-randomized trialMechanism
In women with endometriosis, nafarelin alone at 200 micrograms significantly increased 24-h urinary calcium excretion.
In plain wordsIn women with endometriosis, low-dose nafarelin alone increased urinary calcium excretion.
Peptide
Nafarelin
Outcome
IncreaseUrinary calcium excretion
Study
n: not reported in source
Outcome group
Bone and joint · Kidney and urinary
Studied dose
200 micrograms · 6 monthsAs given in this study (human).
Source sentences
Summary
The 24-h urinary excretion of calcium increased significantly in the groups receiving nafarelin alone, whereas it remained unchanged in the nafarelin plus NET group.
1 context sentence(design, population, supporting numbers)
Summary · context
The same variables were studied in 42 premenopausal women with endometriosis treated for 6 months with nafarelin acetate (a LHRH agonist) given alone in a dose of 200 or 400 micrograms or in a dose of 400 micrograms combined with 1.2 mg norethisterone (NET)/day and followed-up for a further 6 months.
Report a problemFND-0214249107
08HumanNon-randomized trialMechanism
In women with endometriosis, nafarelin alone at 400 micrograms significantly increased 24-h urinary calcium excretion.
In plain wordsIn women with endometriosis, high-dose nafarelin alone increased urinary calcium excretion.
Peptide
Nafarelin
Outcome
IncreaseUrinary calcium excretion
Study
n: not reported in source
Outcome group
Bone and joint · Kidney and urinary
Studied dose
400 micrograms · 6 monthsAs given in this study (human).
Source sentences
Summary
The 24-h urinary excretion of calcium increased significantly in the groups receiving nafarelin alone, whereas it remained unchanged in the nafarelin plus NET group.
1 context sentence(design, population, supporting numbers)
Summary · context
The same variables were studied in 42 premenopausal women with endometriosis treated for 6 months with nafarelin acetate (a LHRH agonist) given alone in a dose of 200 or 400 micrograms or in a dose of 400 micrograms combined with 1.2 mg norethisterone (NET)/day and followed-up for a further 6 months.
Report a problemFND-0214249108

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.